The extension of the SPAN-PD trial showed that CVT-301 maintained its efficacy over 12 months in achieving an ON state in patients experiencing OFF periods, and showed improved efficacy in decreasing daily OFF time and increasing ON time without dyskinesia [1]. During the initial 12-week, double-blind phase, CVT-301 84 mg was associated with significant improvements in Unified Parkinson Disease Rating Scale (UPDRS) motor scores at 30 minutes post-dosing compared to placebo (-9.83 vs -5.91). In addition, 57.7% of patients on CVT-301 84 mg turned ON within 60 minutes after treatment vs 36.1% on placebo [2].
In the extension study, patients from the SPAN-PD study and eligible CVT-301-naïve patients were enrolled. They maintained their usual oral carbidopa/levodopa regimen. All patients were on CVT-301 treatment for OFF periods, but were blinded to dose: 60 mg (n=161) or 84 mg (n=164). At 12 months, 68.4% and 73.0% of patients on CVT-301 60 mg and 84 mg, respectively, achieved an ON state within 60 minutes. These percentages were not significantly different from 1-month values, suggesting that treatment efficacy was maintained. Mean changes in total daily OFF time improved from –0.33 and –0.55 hours at 1 month, to –0.70 and –0.88 hours at 12 months for 60 mg and 84 mg, respectively. Change from baseline in daily ON time without dyskinesia improved from +0.23 and +0.18 hours at 1 month, to +0.32 and +0.40 hours at 12 months.
1. Farbman ES, et al. AAN 2019, P2.8-048.
2. LeWitt PA, et al. Lancet Neurol. 2019;18(2):145-54.
Posted on
Previous Article
« Experimental drug shows promise for SOD1-ALS Next Article
Long-term efficacy and safety of erenumab »
« Experimental drug shows promise for SOD1-ALS Next Article
Long-term efficacy and safety of erenumab »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinson’s Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
New AAN guideline for treating Tourette syndrome
July 30, 2019
Long term safety of diazepam nasal spray
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com